Benserazide Only Product for anemia, sickle cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 16 Jun 2020: Trial registered, NCT04432623
  2. 5 Oct 2020: Trial started, NCT04432623

The trials

NCT04432623: The BENeFiTS Trial in Beta Thalassemia Intermedia

State
Under way
Phase
Phase 1 and Phase 2
People
36 planned
Started
5 Oct 2020
Primary completion
28 Feb 2026
Arms
Low dose, Middle dose, High dose 3 days per week, High dose 5 days per week, Sickle Cell Disease Arm
Results
None posted
  1. 16 Jun 2020: Trial registered
  2. 5 Oct 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.